이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Verrica Pharmaceuticals 배당금

배당금 기준 확인 0/6

Verrica Pharmaceuticals 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.2%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$1.90
3년 후 배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Jan 11

Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation

Jun 28

We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely

Feb 05

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Mar 06

Time To Worry? Analysts Just Downgraded Their Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Outlook

Dec 17

FDA extends review period for Verrica Pharmaceuticals' VP-102 NDA

May 28

Verrica Pharmaceuticals EPS beats by $0.32

May 07

Verrica Pharma refiles US application for lead candidate in infectious skin disease

Dec 23

Verrica Pharma receives final FDA minutes regarding NDA resubmission for VP-102 in molluscum

Nov 17

Verrica Pharma' VP-102 successful in mid-stage study for genital warts

Nov 10

Verrica Pharmaceuticals EPS misses by $0.02

Nov 09

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 VRCA 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: VRCA 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Verrica Pharmaceuticals 시장 대비 배당 수익률

VRCA 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (VRCA)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Pharmaceuticals)	2.2%
3년 후 애널리스트 예측 (VRCA)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 VRCA 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 VRCA 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 VRCA 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: VRCA 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Verrica Pharmaceuticals 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Verrica Pharmaceuticals Inc. Announces Litigation Settlement with Dormer Laboratories, Inc

Price target increased by 10% to US$14.17

No longer forecast to breakeven

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Verrica Pharmaceuticals Inc. to Report Q1, 2024 Results on May 13, 2024

Verrica Pharmaceuticals Inc., Annual General Meeting, Jun 06, 2024

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

Forecast to breakeven in 2026

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Verrica Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 29, 2024

Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH from Centers for Medicare and Medicaid Services

Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Verrica Pharmaceuticals Inc. Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315

Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™? for the Treatment of Common Warts

Forecast to breakeven in 2026

Chief Financial Officer recently sold US$83k worth of stock

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.54 loss per share (vs US$0.002 profit in 3Q 2022)

New minor risk - Profitability

Verrica Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023

Consensus revenue estimates increase by 32%

Consensus revenue estimates fall by 49%

Verrica Pharmaceuticals Inc. Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma At the American Academy of Dermatology 2023 Innovation Academy Meeting

New minor risk - Shareholder dilution

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association's 2023 Innovation Academy Meeting

Insufficient new directors

Chairman of the Board recently bought US$1.0m worth of stock

Consensus revenue estimates decrease by 38%

Verrica Pharmaceuticals Inc. Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum

Consensus revenue estimates fall by 29%

Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation

Consensus revenue estimates increase by 44%

Forecast to breakeven in 2025

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased by 18% to US$11.75

We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely

Forecast to breakeven in 2025

Verrica Pharmaceuticals Inc. Resubmits New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Forecast to breakeven in 2025

Price target decreased to US$10.00

Consensus forecasts updated

Third quarter 2022 earnings released: EPS: US$0.002 (vs US$0.47 loss in 3Q 2021)

Vectoring Back In On Verrica Pharmaceuticals

Consensus revenue estimates increase by 379%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Jakubowitz Law Reminds Verrica Shareholders of a Lead Plaintiff Deadline of August 5, 2022

Director recently bought US$500k worth of stock

Verrica Pharmaceuticals reports insider buying

Verrica Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $25.2 million.

Verrica Pharmaceuticals stock slides on proposed share offering

Verrica Pharmaceuticals Inc.(NasdaqGM:VRCA) dropped from Russell 2000 Growth Index

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Verrica Pharmaceuticals Inc

Consensus forecasts updated

No longer forecast to breakeven

Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC

Price target decreased to US$15.00

Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC

Verrica Pharmaceuticals Should Receive Second CRL Today

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Verrica Pharmaceuticals Inc., Annual General Meeting, Jun 09, 2022

Verrica Pharmaceuticals Inc. Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-In-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

Consensus forecasts updated

Auditors Have Doubts About Verrica Pharmaceuticals (NASDAQ:VRCA)

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Forecast to breakeven in 2024

Time To Worry? Analysts Just Downgraded Their Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Outlook

Verrica Pharmaceuticals Inc. Announces Acceptance by FDA of NDA Resubmission for VP-102

Chairman of the Board recently bought US$468k worth of stock

Verrica Pharmaceuticals Inc. Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum